Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Gut. 2021 Dec;70(12):2398-2400. doi: 10.1136/gutjnl-2021-324116. Epub 2021 Feb 12.

¹ Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK colleen.mcgregor@ndm.ox.ac.uk.
² Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
³ Department of Laboratory Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.
⁵ Departments of Gastroenterology and Paediatric Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK.

No abstract available

Keywords: COVID-19; inflammatory bowel disease; infliximab; paediatric gastroenterology.

Publication types